0001213900-22-079843.txt : 20230117 0001213900-22-079843.hdr.sgml : 20230117 20221214172926 ACCESSION NUMBER: 0001213900-22-079843 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20221214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BiondVax Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 CORRESP 1 filename1.htm

 

BiondVax Pharmaceuticals Ltd.

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

 

December 14, 2022

 

Via EDGAR Transmission

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:   BiondVax Pharmaceuticals Ltd.
    Registration Statement on Form F-1
    Filed September 29, 2022, as amended
    Registration No. 333-267648

 

Ladies and Gentlemen:

 

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on December 15, 2022 at 4:15 p.m. Eastern Time or as soon thereafter as practicable, or at such later time as BiondVax Pharmaceuticals Ltd. (the “Company”) or its counsel may request via telephone call to the staff.

 

Please contact Steven A. Lipstein of Lucosky Brookman LLP, counsel to the Company, at (732) 395-4416, or in his absence, Perry Wildes of Gross & Co., counsel to the Company, at + 972-545651-137, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

 

  Sincerely yours,
     
  BiondVax Pharmaceuticals Ltd.
     
  By:  /s/ Amir Reichman
    Amir Reichman
    Chief Executive Officer

 

cc:

Steven A. Lipstein, Lucosky Brookman LLP

  Perry Wildes, Gross & Co.